Metabolic manifestations of low-dose diuretics (Q41171832)

27 September 2017

1 reference

title

Metabolic manifestations of low-dose diuretics (English)

1 reference

27 September 2017

J M Neutel

1

1 reference

PubMed ID

8876477

27 September 2017

language of work or name

English

0 references

publication date

1 September 1996

1 reference

American Journal of Medicine

27 September 2017

1 reference

27 September 2017

101

1 reference

27 September 2017

3A

1 reference

27 September 2017

71S-82S

1 reference

Mortality and morbidity in relation to systolic blood pressure in two populations with different management of hypertension: The Study of Men Born in 1913 and the Multifactorial Primary Prevention Trial

27 September 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

A comparison of antihypertensive drug effects on the progression of extracranial carotid atherosclerosis. The Multicenter Isradipine Diuretic Atherosclerosis Study (MIDAS)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Effects of long-term physical training on body fat, metabolism, and blood pressure in obesity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Banting lecture 1988. Role of insulin resistance in human disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Cardiovascular and metabolic characteristics of hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Relationship of blood pressure, serum cholesterol, smoking habit, relative weight and ECG abnormalities to incidence of major coronary events: final report of the pooling project. The pooling project research group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Serum lipids, lipoproteins, and apolipoproteins and the excessive occurrence of coronary heart disease in non-insulin-dependent diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Lipoproteins and apolipoproteins in young nonobese Arab women with NIDDM treated with insulin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Microalbuminuria predicts the development of serum lipoprotein abnormalities favouring atherogenesis in newly diagnosed type 2 (non-insulin-dependent) diabetic patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Relationship between lipoprotein levels and in vivo insulin action in normal young white men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Relationships between plasma lipoprotein concentrations and insulin action in an obese hyperinsulinemic population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Heredity and hypertension: Impact on metabolic characteristics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Hyperinsulinemia. A link between hypertension obesity and glucose intolerance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

A prospective study of sodium-lithium countertransport and hypertension in Utah

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Sodium-lithium countertransport and blood pressure: the Gubbio Population Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Correlates of sodium-lithium countertransport. Findings from the Gubbio Epidemiological Study. The Gubbio Collaborative Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Effects of insulin on renal sodium excretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

A role for insulin in the aetiology and course of hypertension?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Salt-sensitive blood pressure and exaggerated vascular reactivity in the hypertension of diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Hyperinsulinemia and the aldosterone and pressor responses to angiotensin II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Does chronic hyperinsulinemia cause hypertension?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Chronic hyperinsulinemia and blood pressure. Interaction with catecholamines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

The hemodynamic response to chronic hyperinsulinemia in conscious dogs.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Hypertension during chronic hyperinsulinemia in rats is not salt-sensitive

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Insulin resistance and hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

[Arterial hypertension in patients with obesity. Role of hyperinsulinism and insulin resistance].

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Clinical review 26: Insulin resistance in obese and nonobese man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Insulin resistance and blood pressure in young black men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Characterization of induction of protooncogene c-myc and cellular growth in human vascular smooth muscle cells by insulin and IGF-I

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Insulin and atheroma. 20-yr perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Overview of the association between insulin and atherosclerosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

The Prospective Cardiovascular Münster (PROCAM) study: prevalence of hyperlipidemia in persons with hypertension and/or diabetes mellitus and the relationship to coronary heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Does potassium supplementation lower blood pressure? A meta-analysis of published trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. Intersalt Cooperative Research Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Hormonal influences on the relationships between body fatness, body fat distribution, lipids, lipoproteins, glucose and blood pressure in French working women.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Mechanisms in obesity-related hypertension: role of insulin and catecholamines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Essential hypertension and insulin resistance in non-insulin-dependent diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Antihypertensive therapy and lipids. Evidence, mechanisms, and implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Effects of isradipine, a new calcium antagonist, versus hydrochlorothiazide on serum lipids and apolipoproteins in patients with systemic hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Metabolic changes with antihypertensive therapy of the salt-sensitive patient

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Effect of alpha- and selective beta-blockade for hypertension control on plasma lipoproteins, apoproteins, lipoprotein subclasses, and postprandial lipemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Adrenergic mechanisms in the control of plasma lipids in man

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Effects of adrenoceptor-blocking drugs on plasma lipoprotein concentrations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Biochemical mechanisms involved in the beta-blocker-induced changes in serum lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Aggravation by propranolol of hyperglycaemic effect of hydrochlorothiazide in type II diabetics without alteration of insulin secretion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Angiographic evolution of coronary atherosclerosis in patients receiving propranolol. A two-year follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Comparison of nifedipine, propranolol and isosorbide dinitrate on angiographic progression and regression of coronary arterial narrowings in angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Role of cellular calcium metabolism in abnormal glucose metabolism and diabetic hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Metabolic effects of antihypertensive therapy with a calcium antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Lack of effect of nicardipine and diltiazem on glucose- and arginine-induced insulin release in obese subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Effect of nicardipine on insulin secretion, glucose and lipid metabolism in hypertensive, non-insulin dependent diabetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Metabolic effects of isradipine versus hydrochlorothiazide in diabetes mellitus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Antihypertensive drugs and glucose metabolism: comparison between a diuretic, a beta-blocker and felodipine, a new calcium antagonist in subjects with arterial hypertension and diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

[Improved insulin action by ACE inhibition in type-2 diabetics]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Lack of effects of angiotensin-converting enzyme (ACE)-inhibitors on glucose metabolism in type 1 diabetes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Glucose and Lipid Metabolism During Long-Term Treatment with Cilazapril in Hypertensive Patients With or Without Impaired Glucose Metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Increase in serum-lipids during treatment of hypertension with chlorthalidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Metabolic parameters after changing from hydrochlorothiazide to verapamil treatment in hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Effects of diuretics on lipid metabolism in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Influence of hydrochlorothiazide on the plasma levels of triglycerides, total cholesterol and HDL-cholesterol in patients with essential hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Increased serum low-density lipoprotein cholesterol in men treated short-term with the diuretic chlorthalidone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Effects of antihypertensive therapy on plasma lipids and lipoproteins in the multiple risk factor intervention trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

The relationship between diuretics and serum cholesterol in Hypertension Detection and Follow-up Program participants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Antihypertensive agents, serum lipoproteins and glucose metabolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Menopause-dependent plasma lipoprotein alterations in diuretic-treated women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

The effect of low-dose hydrochlorothiazide on blood pressure, serum potassium, and lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Combined versus single effect of fosinopril and hydrochlorothiazide in hypertensive patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Comparison of the hemodynamic and metabolic effects of low-dose hydrochlorothiazide and lisinopril treatment in obese patients with high blood pressure.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

A multifactorial trial design to assess combination therapy in hypertension. Treatment with bisoprolol and hydrochlorothiazide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Antihypertensive effect of various doses of hydrochlorothiazide and its relation to the plasma level of the drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Antihypertensive effectiveness of low-dose lisinopril-hydrochlorothiazide combination. A large multicenter study. Lisinopril-Hydrochlorothiazide Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. The East Germany Collaborative Trial Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Controlled multicenter study with quinapril, hydrochlorothiazide, and combination in patients with moderate to severe hypertension.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

Insulin resistance, glucose intolerance and hyperinsulinemia in patients with hypertension

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

7 January 2021

Current knowledge regarding the genetics of human hypertension.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

7 January 2021

Lack of association between blood pressure and insulin in patients with insulinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

7 January 2021

Metabolic Consequences of Treating Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

7 January 2021

Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups.

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9343%2896%2900270-7

7 January 2021

10.1016/S0002-9343(96)00270-7

Identifiers

DOI

1 reference

27 September 2017

1 reference

PubMed ID

8876477